Jefferies Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Target of $8
Benzinga Newsdesk 2 years ago
NewsPrice TargetInitiationAnalyst Ratings
Jefferies analyst Dennis Ding initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $8.
Jefferies analyst Dennis Ding initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $8.